stock price

The GenomeWeb Index outperformed the Nasdaq Biotechnology Index, which lost 5 percent in February, but lost the same amount as the Dow.

The investment bank gave the company's stock an Outperform rating with a target price of $90 per share.

The Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, and reversed the 3 percent loss it saw in December.

Investors in Exact Sciences went on a selling spree after CellMax publicized data suggesting its test could outperform Cologuard for the early detection of colorectal cancer.

The Index also outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, all of which also showed double-digit percentage growth.

The Index underperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index, reversing gains it had made in October and November.

OpGen had previously been warned by Nasdaq that it failed to meet listing requirements. Last week, the firm was told that it was ineligible for an extension to regain compliance.

The investment bank previously had a Neutral rating for the company, and it lowered the price target on Genomic Health's stock to $25 from $28. 

The Index significantly outperformed the Dow, Nasdaq, and Nasdaq Biotechnology Index as it showed double the growth that it had displayed in October.

Thermo Fisher said that it received notice that TRC Capital made an unsolicited mini-tender offer to purchase up to 1 million shares of its stock at $181.75 per share.